Back

Efficacy and safety of sacubitril/valsartan in heart failure with mildly reduced or preserved ejection fraction according to background MRA therapy: a pooled analysis of PARAGLIDE-HF and PARAGON-HF

11 May 2024 (08:00 - 20:00)
Organised by: Logo
Congress Presentation Part of: Chronic heart failure - pathophysiology and mechanisms 8 Heart Failure with Preserved Ejection Fraction (HFpEF) HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Riccardo Maria Inciardi

Civil Hospital of Brescia, Brescia (Italy)

5 More presentations in this session

Presentation thumbnail
Cardiomyocyte-specific overexpression of GCH1 mitigates heart failure with preserved ejection fraction through inhibiting iNOS-mediated nitrosative stress
Doctor Y. Cai (Hung Hom, HK)
Abstract Slides Video
Presentation thumbnail
Machine learning unveils distinctive proteomic signatures in heart failure with preserved ejection fraction: insights into sex-specific profiles
Ms A. Schoeber (Mainz, DE)
Abstract Slides Video
Presentation thumbnail
Prognostic significance of left atrial diameter to left ventricular diastolic diameter ratio in patients with heart failure with preserved ejection fraction
Doctor S. Suzuki (Matsumoto, JP)
Abstract Slides Video
Presentation thumbnail
Use of fluid challenge as a diagnostic tool in patients with dyspnea and preserved ejection fraction
Doctor C. Pereira Mateus (Amadora, PT)
Abstract Slides Video
Presentation thumbnail
Endovascular ablation of the right greater splanchnic nerve in heart failure with preserved ejection fraction: analysis of safety outcomes of the REBALANCE-HF randomized trial
Doctor M. Fudim (Durham, US)
Abstract Slides Video

Access the full session

Session thumbnail
Chronic heart failure - pathophysiology and mechanisms 8

The Event

Event poster

Heart Failure 2024

11 May - 14 May 2024
You may be interested in
thumbnail
Congress Presentation
Influence of ejection fraction on outcomes with sacubitril/valsartan in patients with worsening heart failure with EF>40%: the PARAGLIDE-HF Trial
thumbnail
Congress Presentation
Sacubitril/valsartan vs. valsartan initiation in patients with heart failure and EF>40% who are naive to renin-angiotensin-system inhibitors: Insights from PARAGLIDE-HF
thumbnail
Congress Presentation
Projected lifetime benefits of sacubitril/valsartan on event-free survival in patients with HFmrEF and HFpEF in the PARAGON-HF trial

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources